The symposium continues to push the boundaries of lung cancer care, focusing on innovative therapies and strategies to maximize patient survival. The session opens with vital ESMO updates, specifically addressing novel approaches for targeting historically "undruggable" KRAS-mutated G12C NSCLC. The importance of Comprehensive Genomic Profiling is underscored as an essential tool to stay one step ahead throughout the lung cancer treatment journey. Additionally, the agenda delves into optimizing Overall Survival across different cancer subtypes, featuring discussions on maintenance strategies and clinical evidence from the IMforte trial in Extensive-Stage Small Cell Lung Cancer , as well as the crucial role of first-line choices and sequencing in ALK+ NSCLC. The event concludes with a comprehensive panel discussion to synthesize these advanced clinical insights.